Real World Data on Ide-Cel Efficacy and Side Effects Profile | Rafat Abonour, MD | IMS 2024

Efficacy of Bispecifics in Black Patients in Myeloma Trials | Craig Emmitt Cole, MD | IMS 2024

Selinexor Prior to CAR-T Cell Therapy in Myeloma | Bruno Costa, MD | IMS 2024

Positioning Model to Evaluate CARVYKTI in Second Line vs Later Lines | Rafael Fonseca, MD | IMS 2024

HealthTree Study: Dexamethasone's Impact on Eye Health in Myeloma | Rahul Banerjee, MD | IMS 2024

Linvoseltamab Efficacy in High-Risk RRMM: LINKER-MM1 Study | Attaya Suvannasankha, MD | IMS 2024

Update on MCARH109- a GPRC5D CAR-T Cell for Myeloma | Eric Jergens, MD | IMS 2024

Predictors of delayed responses to teclistamab in myeloma | Rahul Banerjee, MD | IMS 2024

Sequencing bispecific antibodies in myeloma - BCMA or GPRC5D? | Rahul Banerjee, MD | IMS 2024

MILESTONE Trial: MRD Adapted Deferral of Transplant in Dysproteinemia | Susan Bal, MD | IMS 2024

Talquetamab and Teclistamab in RRMM: Updated Results from RedirecTT-1 | Yael Cohen, MD | IMS 2024

Clinical Trial Results for Novel Academic Anti-BCMA Myeloma CAR-T Cell | Yael Cohen, MD | IMS 2024

Newer Therapies for RRMM: Impact on Aging Patients | Suzanne Lentzsch, MD, PhD | IMS 2024

Optimizing Outcomes in Early CAR-T Therapy | Luciano Costa, MD, PhD | IMS 2024

Preliminary Results of Mezigdomide Combinations in RRMM Patients | Luciano Costa, MD, PhD | IMS 2024

An Update on the Use of Bispecific Antibodies in Myeloma | Mohamad Mohty, MD | IMS 2024

Should MRD Guide Myeloma Treatment? A Debate. | Rahul Banerjee, MD and Sridevi Rajeeve, MD |IMS 2024

Timing for Myeloma CAR-T Therapy: A Debate | Rahul Banerjee, MD and Sridevi Rajeeve, MD | IMS 2024

Future Strategies for Managing 2nd Line+ Myeloma: What’s Next? | Leo Rasche, MD | IMS 2024

Unveiling Novel Biomarkers in Myeloma: The Role of CTCs & cfDNA | Bruno Paiva, PhD | IMS 2024

All About Darzalex (Daratumumab) -Updated 2024